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doi:10.1016/j.kjms.2012.04.004Abstract Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/
ARBs) are commonly used in patients with chronic kidney disease (CKD). We studied the status
of ACEI/ARB prescriptions and serum creatinine (Scr) and potassium monitoring in CKD
patients. A retrospective observational study was conducted on patients who had at least
two sets of Scr data at outpatient visit. Estimated glomerular filtration rate (eGFR) based on
the second Scr value was calculated using the Modification of Diet in Renal Disease four-
variable equation. CKD was defined and staged according to the National Kidney Foundation
Disease Outcomes Quality Initiative Guideline. Patients with diabetes and/or hypertension
with an eGFR over 60 mL/min/1.73 m2 and without proteinuria were defined as the CKD-
at-risk group. The percentages and factors associated with ACEI/ARB prescription and Scr
and potassium monitoring were calculated and analyzed by logistic regression. Among the
5714 subjects included, ACEIs/ARBs were prescribed to over 50% of patients in the CKD-
at-risk group and in CKD stages 1e5. After adjusting for age, sex, potassium level, eGFR,
and co-morbidities, the odds ratios for prescriptions of ACEIs/ARBs were 1.66 [95% confidence
interval (CI) 1.44e1.91, p < 0.001) and 2.80 (95% CI 2.12e3.70, p < 0.001) in CKD stage 3, andNephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung
d, Kaohsiung 807, Taiwan.
.tw (S.-J. Hwang).
vier Taiwan LLC. All rights reserved.
478 P.-T. Wang et al.stages 4 and 5, respectively, compared with the reference group (eGFR60 mL/min/1.73 m2).
During the year of ACEI/ARB treatment, Scr was monitored in 91.6% of ACEI/ARB-treated
patients, while potassium was monitored in only 38.1%. Renal function status was the indepen-
dent factor for monitoring of Scr and potassium. In conclusion, prescription of ACEIs/ARBs was
common in all stages of CKD. Most patients underwent Scr monitoring, but potassium moni-
toring was less frequent, and this should be improved in clinical practice.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.Introduction
Angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin receptor blockers (ARBs) have been suggested
by various clinical guidelines for the treatment of patients
with chronic kidney disease (CKD) to delay deterioration in
renal function [1e3], especially as the preferred agents for
diabetic and non-diabetic kidney diseases with proteinuria
[4e7]. However, the use of ACEIs/ARBs is associated with
untoward effects such as hyperkalemia [8], acute renal
failure [9], and cough [8]. It is recommended that blood
levels of potassium and creatinine are monitored at the
beginning of prescription and thereafter to prevent adverse
side effects in patients receiving ACEI/ARB treatment [10].
However, information related to ACEI/ARB prescription
in CKD patients and status of serum creatinine (Scr) and
potassiummonitoring after prescription is lacking in Taiwan.
This study aimed to explore the status of prescription
of ACEIs/ARBs, the monitoring of Scr and potassium, and
the factors associated with monitoring after ACEI/ARB
prescription in CKD patients.Patients and methods
Study subjects
This retrospective study was conducted at a regional
teaching hospital in southern Taiwan. Through the hospital
informatics system, 21,708 subjects who had Scr measure-
ments during an outpatient visit from January 1, 2004 to
December 31, 2005 were screened. The demographics,
disease codes [International Classification of Diseases,
Clinical Modification, 9th Revision (ICD-9-CM)], pharmacy
dispensations, and laboratory data on the patients records
were collected from January 1, 2003 to December 31, 2006.
After excluding subjects with only a single Scr measure-
ment, those with acute conditions (13,583), those younger
than 18 years (535), patients receiving dialysis (277), those
with an eGFR >60 mL/min/1.73 m2 but no diabetes,
hypertension, or proteinuria (1592), and patients with
incomplete ethnic data (7), a total of 5714 patients were
finally included in this study.
Definitions of groups and co-morbidities
Estimated glomerular filtration rate (eGFR), calculated
from second Scr measurement by the Modification of Diet in
Renal Disease four-variable equation [11,12], was defined
as subject’s baseline renal function. Proteinuria/albumin-
uria was defined as at least two occasions of urine protein1þ or greater on urinalysis by dipstick test, a quantitative
measurement of the urine protein to creatinine ratio
exceeding 150 mg/g, or a urine albumin to creatinine ratio
exceeding 30 mg/g during the year before baseline.
Based on the above data, CKD was identified and staged
according to National Kidney Foundation Disease Outcomes
Quality Initiative (NKF-K/DOQI) definitions [13], and patients
in stage 3 CKD were further divided into groups with stage 3a
(eGFR of 45e59 mL/min/1.73 m2) and stage 3b (eGFR of
30e44 mL/min/1.73 m2) disease. Patients of diabetes and/
or hypertension who had an eGFR of over 60mL/min/1.73m2
but no proteinuria were categorized as the CKD-at-risk
group.
Patients who had at least one prescription for ACEIs/
ARBs (excluding those irregular regimens, such as Stat or ‘as
required’) 1 year after baseline were categorized as the
ACEI/ARB group (n Z 3202), in contrast to the non-ACEI/
ARB group (n Z 2512). To study the status of laboratory
monitoring in patients receiving long-term ACEIs/ARBs, Scr
and potassium were traced from the first ACEI/ARB
dispensing date for 995 patients who had received ACEI/
ARB treatment for 1 year with a dispensing gap of less than
60 days within that year.
Based on ICD-9 codes, diabetes (ICD-9-CM 250.x, 357.2,
362.0x, and 366.41) and hypertension (ICD-9-CM 362.11,
401.x-405.x, and 437.2) were defined as at least two
outpatient diagnoses or one inpatient diagnosis before the
baseline date.
Statistical analyses
Results were summarized as mean  standard deviation for
continuous variables and proportions for nominal variables.
Logistic regression was calculated for crude and indepen-
dent associations between potential influenced factors
(demographic factors, co-morbidities, and laboratory
data), the prescription of ACEIs/ARBs, and monitoring of
Scr and potassium after treatment. Multivariable analysis
was expressed by odds ratios (ORs) and the corresponding
95% confidence intervals (CIs). All analyses were performed
using SPSS 12.0 (SPSS Inc., Chicago, IL, USA) for Windows,
with p < 0.05 considered statistically significant. This study
was approved (IRB: KMHK-IRB-96002) by the Institutional
Review Board of Municipal Kaohsiung Hsiao-Kang Hospital.
Results
Characteristics of study populations
The demographic, laboratory, and co-morbidity character-
istics of the 5714 study patients are listed in Table 1. Their
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Prescriptions and monitoring in kidney disease 479average age was 61.4  12.6 years, 54.3% were male, and
56.8% had hypertension. The average Scr and eGFR at
baseline were 1.46 mg/dL and 55.7 mL/min/1.73 m2,
respectively, in all study patients.
Prescription of ACEIs/ARBs
ACEIs/ARBs were prescribed to 3202 patients (56.0%) within
1 year from baseline. Patients in the ACEI/ARB group were
older (62.4  12.5 vs. 60.3  12.9 years, p < 0.001) and had
worse renal function (eGFR 53.6  17.5 vs. 58.4  15.9 mL/
min/1.73 m2, p < 0.001) than the non-ACEI/ARB group, and
a significant proportion of patients had diabetes and/or
hypertension.
Fig. 1 shows the percentages of ACEI/ARB prescriptions
according to co-morbidity and stratified by level of eGFR or
Scr. The percentages of ACEI/ARB prescriptions were 50.2%
of CKD-at-risk, 67.1%, 51.2%, 69.7%, 80.1%, and 64.3% in
CKD stage 1 and 2, 3a, 3b, 4 and 5, respectively (Fig. 1,
upper panel). The percentage declined in patients with
stage 5 CKD.
In patients with an Scr below 1.5 mg/dL, 52.5%
received ACEI/ARB medications. This increased to 82.0% of
patients with an Scr between 3.0 and 4.4 mg/dL, but
decreased to 58.2% of patients with an Scr exceeding
6.0 mg/dL. A higher percentage of patients with an Scr
below 4.5 mg/dL received prescriptions, but once the Scr
increased to over 4.5 mg/dL, the percentage decreased
(Fig. 1, lower panel).The prescription percentages were
highest in the group of patients with both diabetes and
hypertension compared with those of other groups
(Fig. 1).
Factors associated with prescription of ACEIs/ARBs
Lower renal function, diabetes, and hypertension were
associated with higher ACEI/ARB prescription percentages,
as shown in Table 2. Compared with the group with an eGFR
of above 60 mL/min/1.73 m2, the group with an eGFR
between 30 and 59 mL/min/1.73 m2 (OR 1.66, 95% CI
1.44e1.91, p < 0.001) had a higher probability of ACEI/ARB
prescription, as did the group with an eGFR below
30 mL/min/1.73 m2 (OR 2.80, 95% CI 2.12e3.70, p < 0.001),
compared with the reference group, who had an eGFR
60 mL/min/1.73 m2. The presence of diabetes or hyperten-
sionwasalsoassociatedwithahigherprobabilityofACEI/ARB
prescription than the absence of either diabetes or hyper-
tension, and the prescription percentage was even higher in
patients who had both diabetes and hypertension (Table 2).
Monitoring of serum creatinine and potassium
Overall, 911 patients (91.6%) had at least one follow-up Scr
measurement (not including thefirst two Scr readings)within
the study period, including 89.6% of the CKD-at-risk group,
87.9% of those with stages 1 and 2 CKD, 89.6% with stage 3a,
93.8% with stage 3b, 97.5% with stage 4, and 100.0% with
patients with stage 5 disease, as shown in the upper panel of
Fig. 2. The percentagewho underwent potassiummonitoring
was much lower than that for Scr, and only 379 patients
(38.1%) had potassium measurements. The percentages
Figure 1. Percentages of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) prescriptions in all
patients and patients with diabetes (DM) only, hypertension (HTN) only, both DM and HTN, or neither, stratified by stage of chronic
kidney disease (CKD; upper panel) and by serum creatinine (Scr) level (lower panel).
480 P.-T. Wang et al.increased with the severity of CKDd30.3% in patients with
CKD stages 1 and 2, but 72.8% and 94.8% in patients with CKD
stage 4 and stage 5, respectively (Fig. 2, upper panel).
A similar pattern could be noted in groups classified by the
levels of Scr and potassium, as shown in Fig. 2.
Factors associated with laboratory monitoring
Multiple logistic regression analysis of all variables showed
that low renal function and the presence of diabetes were
associated with an increased likelihood of Scr monitoring,
as shown in Table 3. Patients with lower renal function and
with previous potassium measurement showed an increased
likelihood of potassium monitoring. Patients with baseline
potassium data were more likely than those without to be
monitored for potassium level (OR 4.98, 95% CI 3.66e6.79,
p < 0.001) (Table 3).
Discussion
UseofACEIs/ARBs inCKDpatients is recommendedbyvarious
clinical practice guidelines in order to delay deterioration in
renal function [1e3]. We demonstrated that regardless of
whether the patients were in the CKD-at-risk group or had
different stages of CKD, over half of them were prescribed
ACEIs/ARBs. The percentage even reached 80% in CKD with
co-morbidities of both diabetes and hypertension. These
findings reveal the positive attitude of physicians in terms of
following the suggestions in the guidelines and using ACEIs/
ARBs in a significant portion of CKD patients.However, the prescription percentages for ACEIs/ARBs
in CKD patients in this study were even higher than those
seen in other studies, with percentages of around
50e74% [14e18]. The reasons for this are diverse, but
differences in age, the era in which the study was
carried out, and awareness of the effect of ACEIs/ARBs
among physicians could be explanations. The most
dominant population in previous studies [15] was those
above 65 years of age, in contrast to our study, which
had an average age of 64.5 years. Senior age (> 65 years)
is one of factors that might lead to an acute rise in Scr
level [19], and an under use of ACEIs/ARBs could reflect
fear of an increased risk for acute renal failure or
hyperkalemia in elderly patients. The difference in study
period between Nissenson’s study (1994e1997) [15] and
our own (2004e2006) may indicate that physicians today
are more familiar with the usage of ACEIs/ARBs, and
hence use them more frequently.
Since the adverse effects of the ACEIs/ARBs might be
occurring in patients with advanced CKD, this might
decrease the willingness and frequency of use. Berger et al.
[20] reported that approximately half of patients with
chronic heart failure with a GFR below 30 mL/min received
ACEIs/ARBs, and Hsu et al. [21] found that only 27% of
patients with hypertension and a creatinine clearance of
21e40 mL/min were given ACEIs/ARBs. However, in our
results, despite the prescription percentage of ACEIs/ARBs
declining in stage 5 CKD patients, the overall percentages
of ACEI/ARB prescription were still very high in patients
with stages 4 and 5 CKD compared with those seen in other
studies [20,21].
Table 2 Factors associated with use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers among the
study population (n Z 5714).
Characteristics Unadjusted Adjusted
Odds ratio 95% CI p Odds ratio 95% CI p
Age (50 y as reference)
51e64 1.55 1.34e1.79 <0.001 1.00 0.85e1.18 0.98
65 1.25 1.09e1.45 <0.001 1.01 0.85e1.20 0.95
Sex (female as reference) 1.07 0.96e1.19 0.20 1.22 1.09e1.38 <0.001
eGFR (mL/min/1.73 m2, 60 as reference)
30e59 1.18 1.06e1.31 <0.001 1.66 1.44e1.91 <0.001
<30 2.53 2.02e3.17 <0.001 2.80 2.12e3.70 <0.001
Potassium (mmol/L, without Kþ data at baseline as reference)
<3.5 1.56 1.08e2.23 0.02 1.24 0.83e1.86 0.29
3.5e5.5 2.13 1.89e2.39 <0.001 1.87 1.63e2.14 <0.001
>5.5 2.53 1.21e5.27 0.01 1.91 0.81e4.55 0.14
Co-morbidities (neither as reference)
DM alone 2.05 1.72e2.45 <0.001 2.98 2.46e3.61 <0.001
HTN alone 4.89 4.12e5.81 <0.001 6.57 5.45e7.91 <0.001
DM and HTN 14.09 11.58e17.14 <0.001 19.42 15.71e24.01 <0.001
Statistical analysis was carried out using a multiple logistic regression model with adjustment for age, sex, eGFR, potassium level, and
co-morbidities, and expressed as odd ratios with 95% confidence intervals. A value p < 0.05 was considered statistically significant.
DM Z diabetes mellitus; eGFR Z estimated glomerular filtration rate; HTN Z hypertension.
Figure 2. Percentages of serum creatinine (Scr) and potassium (K) measurements in patients who received angiotensin-con-
verting enzyme inhibitor/angiotensin receptor blocker prescriptions, stratified by stage of chronic kidney disease (CKD; upper
panel) and by Scr level (lower panel).
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482 P.-T. Wang et al.In clinical practice, physicians more frequently use Scr
level as a direct marker of renal function. A similar
tendency is also noted for classifications based on Scr level.
The percentage of patients prescribed ACEIs/ARBs tended
to increase for Scr levels below 4.4 mg/dL, but decreased
when the Scr level increased to above 4.5 mg/dL. The trend
in prescription percentages among different Scr groupings
was similar to that of another study [15], which reported
that the percentages of ACEI prescription in patients with
chronic renal insufficiency, either with or without diabetes,
were similar when the Scr was below 3.9 mg/dL regardless
of Scr level, but decreased to less than 20% when Scr was
above 4.0 mg/dL. Because the baseline Scr level of
124 mol/L (1.4 mg/dL) or above is one of the factors leading
to an acute rise in Scr level [19], physicians may hesitate to
prescribe ACEIs as first-line treatment once the GFR rea-
ches 20e25 mL/min or below [22]. Furthermore, almost all
the ACEI/ARB trials have excluded those patients with an
Scr above 3 mg/dL, except for the study by Hou et al. [23],
which recruited patients with an Scr of up to 5 mg/dL. This
could also explain why there was a decrease in prescription
rate in patients with advanced renal failure in our study.
Multivariable analysis showed that patients with lower
renal function were more likely to be prescribed ACEIs/
ARBs in our study. This is because the present study also
included a higher percentage of patients who visited
a nephrologist, and the highest prescription rates were by
nephrologists (data not shown). In addition, over 73% of
patients who visited nephrologists had an Scr above
2.0 mg/dL. Referral of advanced CKD patients to
a nephrologist has been suggested in various studies, citing
the rationale of a better quality of care from a nephrology
team. Schwenger et al. [22] reported that 64% of patients
with a mean Scr of 2.3 mg/dL managed in a nephrology
clinic were prescribed with ACEIs/ARBs. The St. Vincent
Declaration recommended nephrology referral when the
Scr exceeds 200 mol/L (2.26 mg/dL) in order to enable
management of renal failure [24]. Therefore, the higher
percentage of patients with CKD who visited nephrologists
and the higher prescription rates of ACEIs/ARBs in our
study indirectly revealed the importance of referring CKD
patients to nephrologists as soon as possible. In addition,
diabetes and hypertension were two factors that may lead
to patients being prescribed ACEIs/ARBs in this study. This
is mainly due to the positive clinical outcomes and recom-
mendations found in the guidelines [5e7,9].
Scr was evaluated at least once in approximately 92% of
patients after prescription of ACEIs/ARBs during the study
period (Fig. 2), but more than 60% of patients who had
already been prescribed ACEIs/ARBs for a year did not have
their potassium monitored. Multivariable analysis further
showed that patients with lower renal function and with
previous potassium measurement tended to show an
increased likelihood of Scr or potassium monitoring in this
study. These results reflect the pattern of physicians’
prescribing behavior. Patel et al. [25] reported that moni-
toring of kidney function was recommended in approxi-
mately 63% of patients who had CKD with diabetes or/and
hypertension, in compliance with NKF-K/DOQI guidelines.
Serum potassium monitoring could have been less frequent
because of ignorance of the hazards of hyperkalemia and
an overemphasis on Scr measurement in order to obtain
Prescriptions and monitoring in kidney disease 483an eGFR to evaluate renal function. However, whether
monitoring of Scr and K is applied to avoid the adverse
effects of ACEIs/ARBs or for regular follow-up of renal
function, it should be encouraged. Therefore, we suggest
that, in addition to physicians themselves, other members
of the CKD care team, including pharmacists and nurses,
could also play a role in improving the frequency of labo-
ratory monitoring and further improve outcomes in CKD.
The potential limitations of our study should be noted.
First, the generalizability of our findings may be limited by
the fact that this was a retrospective study and was
confined to only one hospital. Second, because fewer than
20% of patients with an eGFR over 60 mL/min/1.73 m2 have
a proteinuria measurement, this may underestimate the
population in the category with stages 1 and 2 CKD. Third,
the entire study cohort had had their Scr monitored during
the previous year, and this may indirectly tend to include
physicians who routinely preferred Scr monitoring. There-
fore, it may overestimate the rate of Scr monitoring.Conclusions
This study shows that prescription of ACEIs/ARBs is common
in patients with CKD with diabetes and/or hypertension,
and that the percentages increase with stage of CKD, as
suggested by various treatment guidelines. Most patients
who received ACEI/ARB medications had their Scr
measured, but potassium monitoring occurred less
frequently, and this should be improved in clinical practice.Acknowledgments
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